Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26962235 | 0.90 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL26962003 | 0.90 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2712060 | 0.86 | SMN1; SMN2 (0.77) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL5141182 | 0.84 | HTT (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL21219729 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL206638 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL25270392 | 0.84 | HTT (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL26626603 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL630153 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL21219740 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4499656-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119183453-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2023192960-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-8143405-B2 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143405-B2 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2077719-B1 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
| EP-2077719-A2 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck and Co., Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008036316-A2 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | SMN1; SMN2 3676/4885NPC1 2177/4885RAB9A 2889/4885 |
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | SMN1; SMN2 1699/4885NPC1 588/4885RAB9A 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.